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Background: We assessed the robustness of passive scattering proton therapy (PSPT) plans for patients in a phase
II trial of PSPT for stage III non-small cell lung cancer (NSCLC) by using the worst-case scenario method, and
compared the worst-case dose distributions with the appearance of locally recurrent lesions.
Methods: Worst-case dose distributions were generated for each of 9 patients who experienced recurrence after
concurrent chemotherapy and PSPT to 74 Gy(RBE) for stage III NSCLC by simulating and incorporating uncertainties
associated with set-up, respiration-induced organ motion, and proton range in the planning process. The worst-case
CT scans were then fused with the positron emission tomography (PET) scans to locate the recurrence.
Results: Although the volumes enclosed by the prescription isodose lines in the worst-case dose distributions were
consistently smaller than enclosed volumes in the nominal plans, the target dose coverage was not significantly
affected: only one patient had a recurrence outside the prescription isodose lines in the worst-case plan.
Conclusions: PSPT is a relatively robust technique. Local recurrence was not associated with target underdosage
resulting from estimated uncertainties in 8 of 9 cases.
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Worst-case scenario methodIntroduction
Radiotherapy has an important role in the management
of locally advanced non-small cell lung cancer (NSCLC)
[1]. However, local control rates after conventional-dose
radiotherapy remain disappointing [2] despite concur-
rent use of chemotherapy. Dose escalation has the po-
tential of improving local control as well as survival if
the higher doses can be delivered safely. The physical
characteristics of protons allow substantial reductions
in the radiation dose to normal tissues while maximi-
zing the dose to the tumor [3,4]. Indeed, we have pub-
lished promising preliminary results from a prospective* Correspondence: jychang@mdanderson.org
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unless otherwise stated.phase II study of proton therapy to a prescribed dose
of 74 Gy(RBE), at 2 Gy(RBE) per fraction, with con-
current carboplatin-paclitaxel chemotherapy for stage
III NSCLC [5].
Although protons can potentially spare more critical
structures than photons can, proton therapy is more
sensitive to uncertainties because of the tissue-density-
dependent finite range of proton beams. The density
variations can be induced by all forms of uncertainties,
including those associated with set-up, organ motion,
and the range uncertainty that is caused by CT number
and proton stopping power uncertainties. Plans that do
not adequately account for uncertainties (i.e., are insuffi-
ciently robust) may be of questionable reliability and
lead to unforeseen outcomes such as local failure and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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robustness of proton-therapy treatment plans is an es-
sential part of the plan-evaluation process.
Several strategies have been developed to deal with ro-
bustness issues in proton therapy [6-11], among which
the worst-case scenario method has been used the most
extensively [12]. This method, first introduced by Lomax
[6], involves simulating different uncertainty scenarios
and incorporating them into the treatment planning
process; we have used this method to assess the ro-
bustness of intensity-modulated proton therapy (IMPT)
plans in clinical practice at our institution [7,8]. How-
ever, to the best of our knowledge, this method has
not been applied for passive scattering proton therapy
(PSPT), nor have potential correlations between plan ro-
bustness and local failure been reported. Here, in the
first such report, we retrospectively evaluated the ro-
bustness of PSPT plans for patients who had experi-
enced local recurrence of NSCLC after PSPT; we used
the 4D worst-case robustness quantification method and




Patients in this secondary analysis were a subset of 44
patients with histologically or cytologically proven stage
III NSCLC (AJCC 2002) enrolled in a prospective phase
II trial of concurrent chemotherapy and proton therapy
[5] (clinicaltrials.gov identifier NCT00495170). The pro-
tocol has been approved by IRB as a phase II clinical
study. Chemotherapy consisted of paclitaxel and carbo-
platin, given as weekly intravenous infusions of 50 mg/m2
paclitaxel and 2-area-under-the-curve units of carboplatin.
Proton therapy was delivered as PSPT as described else-
where [3,5,13] to a total dose of 74 Gy(RBE) in 37 frac-
tions at 2.0 Gy(RBE) per fraction, once per day, and five
fractions per week. Clinical characteristics of the patients
are summarized elsewhere [5,14].
4D Worst-case scenario method and robustness analysis
Plan robustness was analyzed for 9 patients from the
phase II trial who experienced local recurrence by using
the 4D worst-case scenario method. We have reported a
variant of this method that accounts for uncertainties in
set-up and range but not organ motion [7,8]. In the
current study, we also incorporated the potential influ-
ence of intrafractional respiration-related motion into
the worst-case scenarios. For each case, the dose distri-
butions were first recalculated at two breathing phases:
T0 (end-inspiration) and T50 (end-expiration) on the
4D CT scans used for simulation, using the same PSPT
plan as was actually used for treatment (original plan).
Then, we computed 9 different dose distributions foreach phase: the nominal dose distribution (i.e., that with
no consideration of uncertainties) and dose distributions
incorporating (a) set-up uncertainties, obtained by shift-
ing the isocenter of the CT images by ±5 mm along the
anterior-posterior, left-right, and superior-inferior direc-
tions (yielding six dose distributions), and (b) range un-
certainty, by scaling the relative stopping power ratios to
water by ±3.5% (yielding additional two dose distribu-
tions). The uncertainty values for set-up (5 mm) and
range (3.5%) were selected based on those used for PSPT
planning for lung cancer in our clinical practice [3,5,13].
The worst-case dose distribution in every phase was ob-
tained by assigning the lowest of the 9 doses to each
voxel within the clinical target volume (CTV) and the
highest of the 9 doses to each voxel outside the CTV.
The 4D worst-case dose for the patient was then derived
via accumulating the worst-case dose from T0 to T50
phase by using a symmetric force demon registration
method [15]. Plans were evaluated by using the same de-
lineations and definitions of structures as were used in
the original plan.
To visually evaluate the robustness of the PSPT plans,
we extracted the 4D highest (“hot”) and lowest (“cold”)
dose values in each voxel from robustness analysis and
then plotted “banded” dose-volume histograms (DVHs),
which were bounded by the DVHs for the cold and hot
doses to CTV. The width of the DVH bands corresponds
to the robustness of the plan for the target. We further
compared the target coverage of the nominal and 4D
worst-case dose distribution by using two common pa-
rameters for analyzing target coverage: Vprescription-dose
(percentage of the volume receiving at least the prescribed
dose) and D95 (the lowest dose received by 95% of the tar-
get). Because we considered and incorporated uncertain-
ties in the worst-case plans, using a PTV margin (typically
introduced to account for uncertainties) would not be ap-
propriate. Therefore, we chose to evaluate the PTV as the
target volume for the nominal plan but the CTV as the
target volume for the worst-case plan.Correlations between local recurrence and the worst-case
dose distribution
For each patient, the 4D worst-case dose distribution
was displayed on the average simulation CT, with the
isodose lines from 60 to 74 Gy(RBE) at a step size of 2
Gy(RBE). For the purposes of this study, local recurrence
was defined as disease relapse within the PTV on the
average simulation CT at any time, regardless of the tim-
ing of previous failures. The location and volume of the
recurrent lesion relative to the 4D worst-case dose dis-
tribution were evaluated on PET scans on which the re-
currences were first identified, fused with the average
simulation CT scan.
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Update of the clinical outcomes
Median follow-up time for all patients in the trial was
28.5 months (range 6-75 months). Median survival time
was 30 months (95% confidence interval [CI] 16-38);
overall survival (OS) rates were 43.2% at 3 years and
32.1% at 5 years. The median time to progression was
11 months (95% CI 7-15), with progression-free survival
[PFS] rates of 34.6% at both 3 years and 5 years. Locore-
gional recurrence-PFS (LR-PFS) rates were 59.2% at both
3 years and 5 years (Figure 1).
When this analysis was undertaken, a total of 28 pa-
tients had experienced relapse after treatment, 21 with
distant metastasis and 16 with locoregional recurrence
as a component of failure. Among the 16 patients with
locoregional recurrence, recurrence was local only in 4,
regional only in 3, both local and regional in 7, and
unknown for 2 (no images were available from out-
side hospitals).
Robustness analysis
Robustness analyses were undertaken for 9 of the 11 pa-
tients with local recurrence, because the original treat-
ment plans for the other 2 patients had been lost during
an update of the treatment planning system. One of
these 9 patients received adaptive planning and treat-
ment [14] owing to significant shrinkage of the tumor
over the course of treatment. The prescription doses for
the first and second (adaptive) plans for that patient
were 44 Gy and 30 Gy, and we generated two 4D worst-
case dose distributions and evaluated them separately.Figure 1 Kaplan–Meier curves for overall survival (OS),
progression-free survival (PFS), and locoregional-progression-
free survival (LR-PFS).The dose distributions and DVHs used in robustness
analysis of a representative case are shown in Figure 2.
The volume enclosed by the prescription isodose line in
the 4D worst-case dose distribution was smaller than
that in the nominal dose distribution, but inside the
target volume no significant dose difference was found
(Figure 2A), indicating that the uncertainties perturbed
the doses mostly around the marginal regions around
target for PSPT. Figure 2B shows that the DVHs of the
hot and cold doses on the T0 and T50 phases overlap al-
most completely, suggesting that the impact of set-up
and range uncertainty on CTV coverage is almost the
same between different respiratory phases. However, a
slight shift was noted between the 4D accumulated cold
and hot doses and those of the T0/T50 phases resulting
from the dose accumulation that followed the organ mo-
tion from the T0 to T50 phases. The dose distributions
were different both inside and outside CTV between the
T0 and T50 phases (Figure 2C), but the extent of that
difference was generally not significant, especially within
the CTV. The banded DVHs of CTV is shown on
Figure 2D, the narrowness of the band implies that
the PSPT plan was not particularly sensitive to the
treatment uncertainties.
For every patient, the target coverage of the 4D worst-
case dose distribution was slightly lower than that in the
nominal dose distribution, with median differences of
2.8% (range, 0.5%-4.4%) for Vprescription-dose and 1.9 Gy
(range, 0-3.5 Gy) for D95 (Table 1). The comparison of
the DVHs for the CTV in the 4D worst-case dose distri-
bution (the lowest edge of the blue shadow) and for the
PTV in the nominal dose distribution (red line) for the
selected case is also shown in Figure 2D.
The local recurrences appeared within the volume
enclosed by the prescription-dose line of the worst-case
dose distribution in 8 of the 9 patients (c.f. Figure 3), in-
cluding the patient who received the adaptive treatment
(the lesion was covered in both the original and adaptive
plans). The 9th patient had a local recurrence in a sub-
carinal lymph node, outside the 60 Gy(RBE) isodose
lines on the worst-case dose distribution (Figure 4).
However, that node was also outside the 60 Gy(RBE) iso-
dose line in the nominal dose distribution (Figure 4).
Discussion
In this study, we confirmed that dose distributions could
be perturbed by set-up, organ-motion, and range uncer-
tainties in proton therapy, and we further found that any
underdosed regions of the CTV in the 4D worst-case
dose distribution of PSPT always occurred around the
edges of the CTV. This finding was consistent with the
characteristics of PSPT, in which the per-field dose is de-
livered by summing the Bragg peaks from different mono-
energetic protons by using range modulation wheels or
Figure 2 Robustness analyses for a representative case. (A) Axial, sagittal, and coronal views of the dose distributions for the nominal and
worst-case plans and the difference in dose between them (nominal minus worst-case). The white line represents the contoured clinical target
volume (CTV). (B) Dose-volume histogram of the CTV for seven scenarios: the nominal plan and the cold and hot doses on the T0 phase, T50
phase, and 4D accumulated plans. (C) Worst-case dose distributions on the T0 and T50 phases and the differences between them. (D) Banded
dose-volume histogram of the CTV. The blue and red solid lines represent the DVHs for the CTV (blue) and the PTV (red) in the nominal plan.
Table 1 Target coverage in the nominal and worst-case plans
Vprescription dose (%) D95 (Gy)
To PTV (nominal plan) To CTV (worst-case) Difference To PTV (nominal plan) To CTV (worst-case) Difference
Patient 1 90.7 89.1 1.6 72.0 70.9 1.1
Patient 2 93.9 93.4 0.5 73.4 73.4 0
Patient 3 95.6 91.1 3.5 74.2 72.7 1.5
Patient 4 90.0 85.6 4.4 69.2 66.9 2.3
Patient 5 81.0 78.0 3.0 68.9 65.4 3.5
Patient 6 88.1 83.0 4.1 67.3 64.8 2.5
Patient 7 93.0 91.0 2.0 72.0 70.8 1.2
Patient 8 81.1 78.5 2.6 69.4 67 2.4
Patient 9§
1st plan 95.1 93.1 2.0 44.0 43.6 0.4
2nd plan 97.6 93.6 4.0 30.3 29.8 0.5
Abbreviations: Vprescription dose volume (in percent) receiving at least the prescription dose, D95 the minimum dose received by 95% of the target, PTV planning
target volume, CTV clinical target volume.
§Two plans were prepared for this patient during the radiation therapy (“adaptive planning”); the prescribed doses were 44 Gy in the first plans and 30 Gy in
the second.
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Figure 3 Axial, coronal, and sagittal views of fused PET/CT scans showing a local recurrence that occurred within both the 74 Gy(RBE)
(white) isodose lines on the worst-case dose distribution.
Zhu et al. Radiation Oncology 2014, 9:108 Page 5 of 7
http://www.ro-journal.com/content/9/1/108primary and secondary scatters to produce a uniform
dose distribution to cover the whole target per field
(the spread-out Bragg peak [SOBP]). The water-equivalent
length of the plateau part of the SOBP of this field is de-
termined by the target size penetrated by this field. Com-
pensators are used for each individual field to achieveFigure 4 Worst-case (left) and nominal (right) dose-distribution plans
60 Gy(RBE) (red) isodose lines on both set of plans.distal dose conformity in a target volume. Apertures are
also used for each individual field to laterally shape the
dose distribution to protect the critical normal tissues
nearby. The total dose is then formed by fields from dif-
ferent beam angles. The distal and proximal edges of
the SOBPs are determined based on the shapes of targetfor the patient whose local recurrence appeared outside the
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densities along the beam pathways can shift the position
of edges, possibly resulting in underdoses at the marginal
regions of targets. However, the doses to the middle of tar-
gets remain unchanged because the magnitude of the
SOBP is not disturbed.
In this study, we compared the target dose coverage
between the nominal and worst-case dose distributions,
reasoning that it could be a good indicator of the plan’s
robustness because the introduced uncertainties would
lead to target underdosage. Some treatment planning
techniques have already incorporated ways of accounting
for the set-up and range uncertainties in PSPT; for ex-
ample, patient set-up uncertainties are addressed by
expanding the aperture, and range uncertainty by smear-
ing the compensator and by using appropriate beam-
specific distal and proximal margins. Our discovery in
this study that the target dose coverage of the worst-case
dose distribution was smaller than the nominal dose dis-
tribution confirmed the negative effect of uncertainties
on the dose distribution. However, we also observed that
this negative effect was small, meaning that the influence
of the uncertainties on the dose distribution in PSPT
was not significant. Moreover, the analysis of banded
DVHs for the CTV (Figure 2D) also suggested that the
PSPT plan was not sensitive to uncertainties [16]. Col-
lectively, these results demonstrate that our methods
can effectively account for uncertainties in patient set-up
and proton range, and thus that PSPT can be considered
relatively robust with regard to these uncertainties.
In our clinical practice for PSPT planning, the change
in tissue density due to breathing motion is mitigated by
use of averaged 4D CT and integrated-GTV (GTV over
all phases) density override (i.e., assignment of ma-
ximum CT HU number from individual phases). This
method is considered state-of-the-art for accounting for
intrafractional motion, and we have been shown it to be
effective for mitigating the influence of breathing motion
in PSPT [17]. In addition, a specified planning pro-
cess is also used to deal with respiration-induced mo-
tion for PSPT. In this process, we first generate the
original plan on the average simulation CT and then
create two “verification” dose distributions by recalcu-
lating the dose on the 4D simulation CT scans at two
extreme breathing phases (T0 and T50) using the ori-
ginal plan. The original plan is then adjusted until the
verification and original dose distributions all meet the
required prescription criteria. Our finding of little dif-
ference in target coverage in the worst-case dose dis-
tributions between the two phases (Figure 2B) could
reflect the effectiveness of the approaches we applied to
address respiration-induced tumor motion. However,
the fact that there is a difference in the 4D accumulated
worst-case doses from the T0/T50 phases suggests thatrespiratory motion should be included in robustness
analyses.
For 8 of the 9 patients in this study, the volumes of
the recurrent lesions were covered by the prescription
dose on the worst-case dose distribution, suggesting that
these recurrences were unlikely to have been caused by
the uncertainties-induced underdosing; this finding also
indicates that the approaches we used for dealing with
the uncertainties were quite satisfactory for PSPT. One
patient did experience recurrence beyond the region
enclosed by the 60 Gy(RBE) isodose line in the worst-
case dose distribution; however, this lesion was also out-
side the region enclosed by the 60 Gy(RBE) isodose line
on the nominal dose distribution (Figure 4), suggesting
this relapse was not simply related to the dose missing
resulting from uncertainties. Because the primary lesion
in this patient abutted the esophagus, target coverage
was compromised during treatment planning because of
concerns about esophageal toxicity. This example em-
phasizes the importance of target dose coverage for local
control, and it also suggests that a complicated delivery
technique such as IMPT which might be able to spare
the normal tissue better would be better suited for com-
plex cases such as this one [4].
Finally, the incidence of local recurrence (25%) in the
phase II trial of PSPT for lung cancer on which this ana-
lysis was based indicates that the prescribed dose of 74
Gy(RBE) may not be enough to eliminate some inher-
ently radiation-resistant NSCLC tumor cells. A growing
body of evidence [18] now suggests that tumor recur-
rence is associated with failure to eradicate cancer stem
cells, which are tumorigenic, capable of self-renewal, and
relatively radioresistant. Strategies that can enhance the
biological effects of radiation include further dose escal-
ation, use of new dose delivery techniques (e.g., IMPT),
modification of dose-fractionation schedules (e.g., hypo-
fractionated radiotherapy [19] or integrated boost tech-
niques), and use of radiation-sensitizing agents such as
molecular targeted therapy. The effect of these approaches
on cancer stem cells needs further investigation.
Conclusions
The dose distribution of PSPT plan was affected by the
treatment uncertainties, with the underdose area mainly
located on the target margin. The target dose coverage
of the worst-case dose distribution was slightly smaller
than the nominal dose distribution, indicating the ne-
gative effect of uncertainties on the dose distribution
which was not significant in PSPT. Moreover, the ana-
lysis of banded DVHs for the CTV suggested that the
PSPT plan was not sensitive to uncertainties. Thus,
PSPT is a relatively robust technique. Local recurrence
was not associated with target missing due to the robust-
ness issue of PSPT in most cases in our study.
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